CVS Health Corp vs Atlassian Corporation PLC — how do they compare? CVS Health Corp trades at $85.77 (market cap $112.29B), while Atlassian Corporation PLC trades at $204 (market cap $51.53B). The key difference: CVS Health Corp is far larger — about 2.2× Atlassian Corporation PLC's market cap, and CVS Health Corp pays a 3.03% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Atlassian Corporation PLC for 64 Days on average.
| CVS | TEAM | |
|---|---|---|
Market Cap | $112.29B | $51.53B |
Volume | 7,763,676 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $110.60 | $203.57 |
52-Week Low | $70.08 | $57.15 |
Typical Hold Time | 83 Days | 64 Days |
Enterprise Value | $174.64B | $51.52B |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical momentum and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $1.87 exceeding expectations. Revenue growth remains robust at $5.22B in 2025, though profitability challenges persist with negative net margins. Recent news highlights AI-driven growth catalysts and cloud migration success.
Outlook remains positive with 69.77% analyst buy ratings and $191.16 consensus target. Key opportunities include $140B addressable market and AI adoption, while risks involve negative profitability metrics and high valuation multiples. The stock faces execution risk in maintaining growth momentum amid competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →